Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cvs health corp. - CVS

CVS

Close Chg Chg %
57.10 0.23 0.40%

Open Market

57.33

+0.23 (0.40%)

Volume: 2.79M

Last Updated:

Nov 22, 2024, 1:36 PM EDT

Trade Now

Company Overview: cvs health corp. - CVS

CVS Key Data

Open

$57.10

 Day Range

56.62 - 57.62

52 Week Range

52.71 - 83.25

 Market Cap

$71.86B

Shares Outstanding

1.26B

 Public Float

1.26B

Beta

0.54

 Rev. Per Employee

N/A

P/E Ratio

14.51

 EPS

$3.95

Yield

465.85%

 Dividend

$0.67

EX-DIVIDEND DATE

Oct 21, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

12.42M

  

CVS Performance

1 Week
 
 7.35%
 
1 Month
 
 1.08%
 
3 Months
 
 -2.81%
 
1 Year
 
 -17.75%
 
5 Years
 
 -24.18%
 

CVS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 29
Full Ratings ➔

About cvs health corp. - CVS

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS At a Glance

CVS Health Corp.
1 CVS Drive
Woonsocket, Rhode Island 02895
Phone 1-401-765-1500 Revenue 358.27B
Industry Drugstore Chains Net Income 8.34B
Sector Retail Trade 2023 Sales Growth 10.994%
Fiscal Year-end 12 / 2024 Employees 300,000
View SEC Filings

CVS Valuation

P/E Current 14.508
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 12.207
Price to Sales Ratio 0.284
Price to Book Ratio 1.33
Price to Cash Flow Ratio 7.587
Enterprise Value to EBITDA 8.515
Enterprise Value to Sales 0.474
Total Debt to Enterprise Value 0.467

CVS Efficiency

Revenue/Employee 1,194,243.333
Income Per Employee 27,813.333
Receivables Turnover 10.17
Total Asset Turnover 1.451

CVS Liquidity

Current Ratio 0.857
Quick Ratio 0.629
Cash Ratio 0.146

CVS Profitability

Gross Margin 15.331
Operating Margin 4.349
Pretax Margin 3.119
Net Margin 2.329
Return on Assets 3.378
Return on Equity 11.316
Return on Total Capital 5.354
Return on Invested Capital 5.766

CVS Capital Structure

Total Debt to Total Equity 103.824
Total Debt to Total Capital 50.938
Total Debt to Total Assets 30.802
Long-Term Debt to Equity 97.66
Long-Term Debt to Total Capital 47.914
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cvs Health Corp. - CVS

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
268.65B 291.94B 322.79B 358.27B
Sales Growth
+4.71% +8.67% +10.57% +10.99%
Cost of Goods Sold (COGS) incl D&A
219.66B 240.06B 268.17B 303.35B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.44B 4.51B 4.25B 4.37B
Depreciation
2.10B 2.25B 2.44B 2.46B
Amortization of Intangibles
2.34B 2.26B 1.81B 1.91B
COGS Growth
+3.98% +9.29% +11.71% +13.12%
Gross Income
48.99B 51.87B 54.61B 54.93B
Gross Income Growth
+8.09% +5.87% +5.29% +0.57%
Gross Profit Margin
+18.24% +17.77% +16.92% +15.33%
2020 2021 2022 2023 5-year trend
SG&A Expense
35.07B 36.93B 38.21B 39.34B
Research & Development
- - - -
-
Other SG&A
35.07B 36.93B 38.21B 39.34B
SGA Growth
+7.50% +5.31% +3.46% +2.97%
Other Operating Expense
- - - -
-
Unusual Expense
1.77B 2.37B 5.80B 994.00M
EBIT after Unusual Expense
12.15B 12.56B 10.60B 14.59B
Non Operating Income/Expense
492.00M 324.00M (2.70B) (777.00M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.87B 2.47B 2.27B 2.64B
Interest Expense Growth
-4.74% -14.03% -7.98% +16.15%
Gross Interest Expense
2.87B 2.47B 2.27B 2.64B
Interest Capitalized
- - - -
-
Pretax Income
9.77B 10.42B 5.63B 11.17B
Pretax Income Growth
+8.59% +6.65% -45.99% +98.53%
Pretax Margin
+3.64% +3.57% +1.74% +3.12%
Income Tax
2.57B 2.52B 1.46B 2.81B
Income Tax - Current - Domestic
3.13B 2.95B 3.54B 3.48B
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(564.00M) (428.00M) (2.08B) (676.00M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
7.20B 7.90B 4.17B 8.37B
Minority Interest Expense
13.00M (12.00M) 16.00M 24.00M
Net Income
7.19B 7.91B 4.15B 8.34B
Net Income Growth
+8.43% +10.04% -47.55% +101.11%
Net Margin Growth
+2.68% +2.71% +1.29% +2.33%
Extraordinaries & Discontinued Operations
- - - (9.00M)
-
Discontinued Operations
- - - (9.00M)
-
Net Income After Extraordinaries
7.18B 7.91B 4.15B 8.34B
Preferred Dividends
- - - -
-
Net Income Available to Common
7.18B 7.91B 4.15B 8.34B
EPS (Basic)
5.4843 5.997 3.1624 6.4934
EPS (Basic) Growth
+7.63% +9.35% -47.27% +105.33%
Basic Shares Outstanding
1.31B 1.32B 1.31B 1.28B
EPS (Diluted)
5.4635 5.9518 3.136 6.4682
EPS (Diluted) Growth
+7.56% +8.94% -47.31% +106.26%
Diluted Shares Outstanding
1.31B 1.33B 1.32B 1.29B
EBITDA
18.36B 19.45B 20.65B 19.95B
EBITDA Growth
+7.76% +5.92% +6.16% -3.39%
EBITDA Margin
+6.84% +6.66% +6.40% +5.57%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 66.318
Number of Ratings 29 Current Quarters Estimate 1.114
FY Report Date 12 / 2024 Current Year's Estimate 5.425
Last Quarter’s Earnings 1.09 Median PE on CY Estimate N/A
Year Ago Earnings 8.74 Next Fiscal Year Estimate 6.303
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 22 16 24 24
Mean Estimate 1.11 1.34 5.42 6.30
High Estimates 1.63 1.73 6.47 7.96
Low Estimate 0.60 1.01 4.83 5.26
Coefficient of Variance 25.16 11.78 7.59 10.33

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 15 14 11
OVERWEIGHT 3 2 1
HOLD 11 12 16
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Cvs Health Corp. - CVS

Date Name Shares Transaction Value
May 3, 2024 Edward J. Ludwig Director 21,630 Open market or private purchase of non-derivative security Non-derivative transaction at $53.88 per share 1,165,424.40
May 3, 2024 Michael F. Mahoney Director 9,356 Open market or private purchase of non-derivative security Non-derivative transaction at $54.49 per share 509,808.44
Mar 4, 2024 J. David Joyner EVP&President-PharmacyServices 40,681 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $75.19 per share 3,058,804.39
Mar 4, 2024 Samrat S. Khichi EVP, CPO and General Counsel 9,750 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $75.19 per share 733,102.50
Mar 4, 2024 Thomas F. Cowhey SVP, Interim CFO 28,631 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $75.19 per share 2,152,764.89
Feb 29, 2024 Laurie P. Havanec EVP and Chief People Officer 45,183 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $76.43 per share 3,453,336.69
Feb 29, 2024 Prem S. Shah EVP and Pres-Pharm, Consumer W 43,185 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $76.43 per share 3,300,629.55
Feb 29, 2024 Sreekanth Chaguturu EVP and Chief Medical Officer 9,334 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $76.43 per share 713,397.62
Feb 15, 2024 Karen S. Lynch President and CEO; Director 136,640 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 15, 2024 James D. Clark SVP, Cont & Chief Acct Officer 7,150 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 13, 2023 Anne M. Finucane Director 7,232 Bona fide gift Non-derivative transaction at $74.28 per share 537,192.96

Cvs Health Corp. in the News

Markets

CVS Health to cut 2,900 jobs

CVS Health is slashing its headcount by 2,900, or 1% of its total workforce. The layoffs will largely focus on corporate positions, a spokesperson said.

Markets

Meet Disney's newly elected board

Disney CEO Bob Iger will be working closely with his newly elected board, which boasts a handful of current and former Fortune 500 executives and some niche corporate insiders.